JPH09278661A - Suspension formulation - Google Patents

Suspension formulation

Info

Publication number
JPH09278661A
JPH09278661A JP8110385A JP11038596A JPH09278661A JP H09278661 A JPH09278661 A JP H09278661A JP 8110385 A JP8110385 A JP 8110385A JP 11038596 A JP11038596 A JP 11038596A JP H09278661 A JPH09278661 A JP H09278661A
Authority
JP
Japan
Prior art keywords
suspension
vol
suspension formulation
bitterness
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8110385A
Other languages
Japanese (ja)
Inventor
Mitsuji Inagaki
満二 稲垣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Chemical Industries Co Ltd
Original Assignee
Fuji Chemical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Chemical Industries Co Ltd filed Critical Fuji Chemical Industries Co Ltd
Priority to JP8110385A priority Critical patent/JPH09278661A/en
Publication of JPH09278661A publication Critical patent/JPH09278661A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PROBLEM TO BE SOLVED: To prepare a readily drinkable suspension formulation, soft and pleasant to the palate, having masked strong bitterness of a digestive agent and stable and good in uniformity even when preserved for a long period. SOLUTION: This suspension formulation comprises 0.01-0.05wt./vol.% digestive agent (e.g. ursodeoxycholic acid), 2-20wt./vol.% inorganic antacid (e.g. magnesium metasilicate aluminate), 0.01-5wt./vol.% xanthan gum and 0.1-20wt./vol.% modified starch (e.g. hydroxypropyl starch) as active ingredients. Furthermore, usual ingredients are suitably blended therewith and the resultant blend as converted into a uniform suspension by using a homogenizer, etc., according to a conventional method and, as necessary, sterilized by heating, etc., to afford the objective substance. The suspension formulation is capable of maintaining a stable suspended state even when preserved for a long period and the redispersion thereof can readily by carried out in a short time even in the case of performing the sedimenting and separating. Furthermore, the suspension formulation is effective in promoting digestion and reducing symptoms such as gastric and abdominal inflations, gastralgia or gastric hyperacidity caused by dyspepsia, anorexia, excessive eating, a dull feeling in the stomach or lying of foods heavy in the stomach.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、消化剤、無機制酸剤、
キサンタンガム及び化工デンプンからなることを特徴と
する懸濁液剤に関する。
The present invention relates to a digestive agent, an inorganic antacid,
It relates to a suspension agent comprising xanthan gum and modified starch.

【0002】[0002]

【従来技術】消化剤及び制酸剤などの製剤は、消化促
進、消化不良、食欲不振、食べ過ぎ、胃もたれ、胸つか
え、消化不良などによる胃部・腹部膨満感、胃痛、胃酸
過多などの症状の改善に用いられる。上記製剤は、通
常、顆粒剤又は錠剤などの固形製剤として用いられるこ
とが多かった。それは消化剤の利胆剤が服用者が受付ら
れないほど苦味が非常に強いため、これを緩和するため
に固形剤であればフイルムコーチィングする方法や包接
化合物化などの手段で行うことが比較的容易であるため
である。しかしながら、固形製剤では服用後、胃内での
崩壊や分散に時間を要し、結果として薬効の出現が遅延
し、症状を速やかに改善できないという問題があった。
この問題を解決する方法として、胃内で製剤中の有効成
分が容易に分散し得る液剤の出現が望まれていた。また
このような消化剤及び制酸剤を使用する液剤は、舌触り
などを良くし、飲み易くするために均一に懸濁分散化し
ていること、且つ味の面からは消化剤の強い苦味が充分
にマスキングされていることが必要である。ところが無
機制酸剤を含有する液剤を均一に懸濁させ、且つ消化剤
の苦味をマスキングすることは容易でなく、苦味がマス
キングできても懸濁安定性が悪くなり、逆に均一に懸濁
させることができても苦味のマスキングが不完全にな
り、これらを両立化した懸濁液剤は未だ報告されていな
い。又、液剤の安定性が良好であっても長期間保存する
ことにより劣化し、一旦、沈降分離した後に再度分散さ
せようとする場合には多大の労を要するなどの問題があ
った。
2. Description of the Related Art Preparations such as digestive agents and antacids are used for promoting digestion, dyspepsia, loss of appetite, overeating, stomach upset, chest tightness, bloating due to indigestion, gastric pain, hypergastric acid, etc. Used to improve symptoms. The above-mentioned preparations were usually used as solid preparations such as granules or tablets. The bitterness of digestive choleretic agents is so strong that they cannot be accepted by users, so in order to alleviate this, solid coatings can be done by film coating or inclusion compounding means. This is because it is easy. However, the solid preparation has a problem that it takes time to disintegrate or disperse in the stomach after taking the drug, resulting in delaying the onset of the medicinal effect and not rapidly improving the symptoms.
As a method for solving this problem, the emergence of a liquid agent in which the active ingredient in the preparation can be easily dispersed in the stomach has been desired. In addition, liquids using such digestive agents and antacids are uniformly suspended and dispersed in order to improve the texture of the tongue and make it easy to drink, and from the aspect of taste, the strong bitterness of the digestive agent is sufficient. Must be masked by. However, it is not easy to uniformly suspend a liquid agent containing an inorganic antacid, and to mask the bitterness of the digestive agent. Even if it can be done, the masking of bitterness becomes incomplete, and a suspension agent that makes them compatible has not been reported yet. Further, even if the stability of the liquid agent is good, it deteriorates after being stored for a long period of time, and there is a problem that a great deal of labor is required when it is once separated by sedimentation and then dispersed again.

【0003】[0003]

【発明が解決しようとする課題】本発明は、舌触りなど
が良くて飲み易く、消化剤の強い苦味がマスキングされ
ていて、且つ長期間保存しても無機制酸剤などの成分が
安定な懸濁状態を維持でき、しかも、一旦沈降分離した
場合であっても容易に再分散させることができる懸濁液
剤を提供することを目的とする。
DISCLOSURE OF THE INVENTION The present invention has a good texture on the tongue and is easy to drink, masks the strong bitterness of the digestive agent, and has stable ingredients such as an inorganic antacid even after long-term storage. An object of the present invention is to provide a suspension agent which can maintain a turbid state and can be easily redispersed even if it is once separated by sedimentation.

【0004】[0004]

【課題を解決するための手段】本発明者らは、上記課題
を解決するために鋭意研究を重ねた結果、分散剤として
キサンタンガムと化工デンプンを組み合わせて用いるこ
とにより、消化剤の苦味がマスキングされ、且つ長期間
保存しても安定な懸濁状態を維持することができること
を見い出した。本発明は係る知見に基づいてなされたも
のである。すなわち、本発明は、0.01〜0.05W
/V%の消化剤、2〜20W/V%の無機制酸剤、0.
01〜5W/V%のキサンタンガム、0.1〜5W/
V%の化工デンプンからなることを特徴とする懸濁液剤
である。
Means for Solving the Problems As a result of intensive studies to solve the above-mentioned problems, the present inventors used xanthan gum and modified starch in combination as a dispersant to mask the bitterness of the digestive agent. It has been found that a stable suspended state can be maintained even after long-term storage. The present invention has been made based on such findings. That is, the present invention is 0.01 to 0.05 W
/ V% digestive agent, 2-20 W / V% inorganic antacid, 0.
01-5 W / V% xanthan gum, 0.1-5 W /
It is a suspension agent characterized by comprising V% of modified starch.

【0005】本発明において用いられる消化剤として
は、利胆剤、例えば、ウルソデスオキシコール酸、オキ
シコーラン酸、デヒドロコール酸、コール酸、胆汁末、
胆汁エキス、動物胆などを挙げることができる。本発明
においては、上記利胆剤の1種又は2種以上を併用して
用いることもできる。上記利胆剤の配合量は懸濁液剤の
全液量に対して0.01〜0.05W/V%、好ましく
は0.01〜0.025W/V%である。
The digestive agents used in the present invention include choleretic agents such as ursodesoxycholic acid, oxycholanic acid, dehydrocholic acid, cholic acid, bile powder,
Bile extract, animal gall, etc. can be mentioned. In the present invention, one type or two or more types of the above-mentioned choleretic agents can be used in combination. The compounding amount of the above-mentioned bile agent is 0.01 to 0.05 W / V%, preferably 0.01 to 0.025 W / V% with respect to the total amount of the suspension.

【0006】無機制酸剤としては、特に限定されるもの
ではないが、本発明においては非水溶性制酸剤がより好
ましい。非水溶性無機制酸剤としては、例えば、水に不
溶性の金属酸化物、金属水酸化物、金属酸塩又は複合金
属化合物などを挙げることができる。より具体的には、
例えば、酸化マグネシウムなどの金属酸化物、水酸化ア
ルミニウム、水酸化マグネシウムなどの金属水酸化物、
炭酸カルシウム、炭酸マグネシウムなどの金属炭酸塩、
又はメタケイ酸アルミン酸マグネシウム、ケイ酸アルミ
ン酸マグネシウム、水酸化アルミナマグネシア、合成ヒ
ドロキシタルサイトなどの複合金属化合物などの中から
適宜選択した1種又は2種以上を用いることができる。
本発明のより好ましい組み合わせとしては、水酸化アル
ミニウム、水酸化マグネシウム、メタケイ酸アルミン酸
マグネシウム、ケイ酸アルミン酸マグネシウム、又は合
成ヒドロキシタルサイトを単独、又は2種以上を組合せ
て用いた場合である。これら制酸剤の配合量は懸濁液剤
の全量に対して通常固形物として2〜20W/V%、好
ましくは5〜15W/V%である。上記無機制酸剤は天
然物又は合成品由来のものであっても良く、特に制限は
ないが、すでに粉末となったものを用いる場合には出来
るだけ微粉に粉砕して用いる方が好ましい。又、合成品
を用いる場合には、必要に応じて合成品を乾燥させる前
のペースト状のものを用いることもできる。上記無機制
酸剤の粒子径としては、0.1〜10μmのものが好ま
しく、0.1〜5μmのものが特に好ましい。本発明に
は上記制酸剤に加えて炭酸水素ナトリウムなどの水溶性
無機制酸剤を必要に応じて加えることができる。これら
の水溶性無機制酸剤の使用量は本発明の懸濁液剤の懸濁
の均一性及び再分散性に影響を及ぼさない範囲であれば
自由に使用することができる。
The inorganic antacid is not particularly limited, but a water-insoluble antacid is more preferable in the present invention. Examples of the water-insoluble inorganic antacid include water-insoluble metal oxides, metal hydroxides, metal acid salts and complex metal compounds. More specifically,
For example, metal oxides such as magnesium oxide, aluminum hydroxide, metal hydroxides such as magnesium hydroxide,
Metal carbonates such as calcium carbonate and magnesium carbonate,
Alternatively, it is possible to use one kind or two or more kinds appropriately selected from composite metal compounds such as magnesium aluminate metasilicate, magnesium aluminate silicate, alumina magnesia hydroxide, and synthetic hydroxytalcite.
A more preferable combination of the present invention is the case where aluminum hydroxide, magnesium hydroxide, magnesium aluminometasilicate, magnesium aluminate silicate, or synthetic hydroxytalcite is used alone or in combination of two or more kinds. The compounding amount of these antacids is usually 2 to 20 W / V%, preferably 5 to 15 W / V% as a solid matter with respect to the total amount of the suspension agent. The above-mentioned inorganic antacid may be derived from a natural product or a synthetic product and is not particularly limited. However, when a powdered product is used, it is preferable to use it by pulverizing it into a fine powder as much as possible. Further, when the synthetic product is used, a paste-like product before drying the synthetic product can be used if necessary. The particle size of the inorganic antacid is preferably 0.1 to 10 μm, particularly preferably 0.1 to 5 μm. In the present invention, in addition to the above antacid, a water-soluble inorganic antacid such as sodium hydrogen carbonate can be added if necessary. The amount of these water-soluble inorganic antacids to be used can be freely used as long as it does not affect the suspension uniformity and redispersibility of the suspension of the present invention.

【0007】キサンタンガムとしては、発酵多糖類を精
製した天然ガム質で、水に対して澄明溶解型のものと不
透明分散型のものを挙げることができる。本発明ではい
ずれを用いてもよくまた併用してもよい。より具体的に
は市販品、例えばエコーガム(商品名、大日本製薬
製)、ネオソフト(商品名、興人製)又はローディンゲ
ル(商品名、ロヌプーラン・ジャパン製)などを挙げる
ことができる。これらキサンタンガムの配合量は懸濁液
剤の全量に対して、0.01〜5W/V%、好ましくは
0.05〜1W/V%である。
Examples of the xanthan gum include natural gums obtained by refining fermented polysaccharides, those that are clear and soluble in water and those that are opaque and dispersed. In the present invention, any of these may be used or they may be used in combination. More specific examples include commercially available products such as Echo Gum (trade name, manufactured by Dainippon Pharmaceutical), Neosoft (trade name, manufactured by Kojin), and Rodingel (trade name, manufactured by Ron Poulenc Japan). The blending amount of these xanthan gum is 0.01 to 5 W / V%, preferably 0.05 to 1 W / V% with respect to the total amount of the suspension agent.

【0008】化工デンプンとしては、デンプン誘導体の
ヒドロキシプロピルスターチや、デンプンを加熱処理し
部分的にアルファー化した部分アルファー化デンプン、
及び酸などと共に加水分解して得られるデキストリンな
どを挙げることができる。より具体的には市販品、例え
ばHPS(商品名、フロイント産業製)などのヒドロキ
シプロピルスターチ;PCS(商品名、旭化成工業製)
及びスターチ1500(商品名、日本カラコン製)など
の部分アルファー化デンプン;デキストリン(商品名、
日澱化学製)又はパインデックス(商品名、松谷化学工
業製)などのデキストリンなどを挙げることができる。
上記加工デンプンの配合割合は、懸濁液剤の全量に対し
て好ましくは0.1〜20W/V%であり、より好まし
くは1〜5W/V%である。
Examples of the modified starch include hydroxypropyl starch, which is a starch derivative, and partially pregelatinized starch which is partially pregelatinized by heat-treating starch.
And dextrin obtained by hydrolysis with acid and the like. More specifically, commercially available products such as hydroxypropyl starch such as HPS (trade name, manufactured by Freund Sangyo); PCS (trade name, manufactured by Asahi Kasei Kogyo)
And partially pregelatinized starch such as Starch 1500 (trade name, manufactured by Nippon Colorcon); dextrin (trade name,
Examples thereof include dextrin such as Nitto Kagaku) or Paindex (trade name, manufactured by Matsutani Chemical Co., Ltd.).
The blending ratio of the modified starch is preferably 0.1 to 20 W / V%, and more preferably 1 to 5 W / V% with respect to the total amount of the suspension agent.

【0009】本発明の懸濁液剤には上記成分のほかに、
D−ソルビトール、濃グリセリン又はマンニトールなど
の多価アルコール、ケイヒ、チョウジ、赤芽柏、カンゾ
ウなどの生薬類、ジメチルポリシロキサン又はシリコン
樹脂などの消泡剤、パラオキシ安息香酸メチル、安息香
酸ナトリウムなどの防腐剤、ハッカ油、メントール、レ
モン油などの香料、サッカリンナトリウム又はグリチル
リチン酸などの甘味剤を必要に応じて加えることができ
る。これらの成分は、医薬品や食品などの製造に際し、
一般的に用いられるものを適宜、単独又は併用すること
ができ、特に制限されるものではない。
In addition to the above components, the suspension of the present invention comprises
Polyhydric alcohols such as D-sorbitol, concentrated glycerin or mannitol, crude drugs such as cinnamon bark, clove, red bud, licorice, antifoaming agents such as dimethylpolysiloxane or silicone resin, preservatives such as methyl paraoxybenzoate and sodium benzoate. If desired, flavoring agents such as peppermint oil, menthol, and lemon oil, and sweetening agents such as sodium saccharin or glycyrrhizic acid can be added. These ingredients are used in the production of pharmaceuticals and foods,
Those generally used can be used alone or in combination, and are not particularly limited.

【0010】本発明の懸濁液剤は、通常の水性懸濁剤の
製法に従って製造できる。すなわち、適量の精製水を貯
えた容器に前述の成分をそのままか、予め精製水に溶解
した上で加え、ホモジナイザーなどによって均一な懸濁
液として必要により加熱などにより殺菌を行えばよい。
本発明の懸濁液剤の好適な組み合わせとしては、例え
ば、D−ソルビトール、キサンタンガム、ヒドロキシプ
ロピルスターチ、メタケイ酸アルミン酸マグネシウム及
びウルソデスオキシコール酸からなるものを挙げること
ができる。
The suspension of the present invention can be produced by a conventional method for producing an aqueous suspension. That is, the above-mentioned components may be added to a container containing an appropriate amount of purified water as it is or after being dissolved in purified water in advance, and a homogenizer or the like may prepare a uniform suspension for sterilization by heating if necessary.
As a suitable combination of the suspension agent of the present invention, for example, a combination of D-sorbitol, xanthan gum, hydroxypropyl starch, magnesium aluminometasilicate and ursodesoxycholic acid can be mentioned.

【0011】本発明の懸濁液剤及び比較対照の懸濁液剤
の製造法を以下の実施例及び参考例に、又該当する懸濁
液剤中の各成分を表1に示す。
The method for producing the suspension of the present invention and the suspension for comparison and comparison are shown in the following Examples and Reference Examples, and Table 1 shows each component in the suspension.

【実施例】【Example】

実施例1 1.5Lの容器に精製水620gを入れ、撹拌しながら
D−ソルビトール200g、キサンタンガム3g、ヒド
ロキシプロピルスターチ45g、パラオキシ安息香酸メ
チル1g、メタケイ酸アルミン酸マグネシウム80g、
ウルソデスオキシコール酸0.2gをそれぞれ順次加え
均一分散し、更に80℃まで分散液を昇温する。その後
冷却しL−メントール1gを添加した後、精製水で全液
量を1000mlに調整した。得られた懸濁液の粘度は
182cpであった。主な処方成分を表1に示した。 実施例2〜3 実施例1の方法に準じて表1に示す処方の懸濁液剤を1
000mlづつ製造した。得られた懸濁液の粘度はそれ
ぞれ98cp、220cpであった。 実施例4 実施例1の方法に準じて表1に示す処方で懸濁液剤を1
000ml調製した後ホモジナイザーにて処理した。得
られた懸濁液剤の粘度は142cpであった。
Example 1 620 g of purified water was put in a 1.5 L container, and 200 g of D-sorbitol, 3 g of xanthan gum, 45 g of hydroxypropyl starch, 1 g of methyl paraoxybenzoate, 80 g of magnesium aluminometasilicate, while stirring.
0.2 g of ursodesoxycholic acid was sequentially added to each and uniformly dispersed, and the temperature of the dispersion was further raised to 80 ° C. After cooling, 1 g of L-menthol was added, and the total amount of liquid was adjusted to 1000 ml with purified water. The viscosity of the obtained suspension was 182 cp. The main prescription ingredients are shown in Table 1. Examples 2 to 3 According to the method of Example 1, 1 of the suspension agent having the formulation shown in Table 1 was prepared.
Each 000 ml was manufactured. The viscosities of the obtained suspensions were 98 cp and 220 cp, respectively. Example 4 According to the method of Example 1, 1 suspension liquid was prepared according to the formulation shown in Table 1.
After preparing 000 ml, it was treated with a homogenizer. The viscosity of the obtained suspension was 142 cp.

【0012】参考例1〜3 実施例1の方法に準じて表1に示す処方の参考例1〜3
の懸濁液剤を各々1000mlづつ製造した。得られた
懸濁液の粘度はそれぞれ16cp、111cp及び96
cpであった。
Reference Examples 1 to 3 Reference Examples 1 to 3 of the formulations shown in Table 1 according to the method of Example 1.
1000 ml of each suspension was prepared. The viscosities of the resulting suspensions were 16 cp, 111 cp and 96, respectively.
cp.

【0013】[0013]

【表1】 [Table 1]

【0014】I.安定性試験(沈降性及び再分散性):
上記実施例及び参考例で調製した懸濁液剤を用いて、安
定性試験(沈降性及び再分散性)を行った。その結果は
表2に示すとおりであった。
I. Stability test (settling and redispersibility):
Stability tests (sedimentability and redispersibility) were conducted using the suspensions prepared in the above Examples and Reference Examples. The results were as shown in Table 2.

【0015】[0015]

【表2】 [Table 2]

【0016】表2の結果からは、実施例1〜4の処方で
得られる本発明の懸濁液剤は、長期間保存しても沈降分
離が起こり難く、且つ再分散性が極めて良好であること
がわかる。一方、参考例1の処方の懸濁液剤は沈降分離
が激しく、再分散させることが極めて困難な製剤であ
る。参考例2の懸濁液剤については沈降分離は起こり難
く分散性もほぼ良好である。又、参考例3の懸濁液剤は
沈降分離が参考例1のものほどではないが未だ大きく、
しかも加温条件下で次第に沈降率が増加する傾向を示
し、又再分散させるにも困難性を伴うものである。
From the results shown in Table 2, the suspensions of the present invention obtained by the formulations of Examples 1 to 4 are resistant to sedimentation and separation even after long-term storage, and have extremely good redispersibility. I understand. On the other hand, the suspension of the formulation of Reference Example 1 is a formulation that is extremely difficult to re-disperse because it undergoes severe sedimentation separation. The suspension agent of Reference Example 2 is unlikely to cause sedimentation and separation and has good dispersibility. Further, the suspension agent of Reference Example 3 has a larger sedimentation separation than that of Reference Example 1, but is still large,
Moreover, the settling rate tends to gradually increase under heating conditions, and it is difficult to redisperse it.

【0017】試験方法 (1)室温静置試験: 製造直後の懸濁液200mlを円柱形のガラス瓶にとり、
室温にて3ヶ月間静置した後、上澄液の高さを読みとり
全液高に対する比率を計算した。 (2)40℃静置試験 製造直後の懸濁液200mlを円柱間のガラス瓶にとり、
40℃にて3ヶ月静置した後、上記と同様の測定を行っ
た。 (3)50℃静置試験 製造直後の懸濁液200mlを円柱間のガラス瓶にとり、
50℃にて2ヶ月静置した後、上記と同様の測定を行っ
た。 (4)遠心分離試験 製造直後の懸濁液50mlを目盛付きガラス製の共栓付き
遠沈管にとり、2000rpmで15分間遠心分離を行
った後、上澄液の量を読みとり全液量に対する比率を計
算した。 (5)再分散試験(1) 室温及び40℃にて3ヶ月間、及び50℃にて2ヶ月間
それぞれ静置し上澄液の量を読みとった後の検体をその
まま横向きとし、毎分200往復で振とうして1分毎に
懸濁液の状態を観察し、均一分散するまでの時間を分単
位で求めた。 (6)再分散性(2) 遠心分離試験後の検体をそのまま倒立させて、毎分20
0往復で振とうして1分毎に懸濁液の状態を観察し、均
一分散するまでの時間を分単位で求めた。
Test method (1) Room temperature static test: 200 ml of the suspension immediately after production was placed in a cylindrical glass bottle,
After standing at room temperature for 3 months, the height of the supernatant was read and the ratio to the total height was calculated. (2) 40 ° C. static test 200 ml of the suspension immediately after production was placed in a glass bottle between columns,
After standing at 40 ° C. for 3 months, the same measurement as above was performed. (3) Static test at 50 ° C. 200 ml of the suspension immediately after production was placed in a glass bottle between columns,
After standing at 50 ° C. for 2 months, the same measurement as above was performed. (4) Centrifugation test 50 ml of the suspension immediately after production was placed in a glass centrifuge tube with a stopper and centrifuged at 2000 rpm for 15 minutes. I calculated. (5) Redispersion test (1) The sample was left standing at room temperature and 40 ° C. for 3 months and at 50 ° C. for 2 months, and the amount of the supernatant was read. The suspension was shaken back and forth to observe the state of the suspension every minute, and the time until uniform dispersion was obtained in minutes. (6) Redispersibility (2) The sample after the centrifugation test is inverted up to 20 minutes per minute.
The state of the suspension was observed every 1 minute by shaking with 0 reciprocations, and the time until uniform dispersion was obtained in minutes.

【0018】II.苦味評価試験 実施例及び参考例で調製した懸濁液剤を用いて苦味評価
試験を行った。その結果は表3に示すとおりであった。 (試験方法)パネラー10名(男子8名、女子2名)に
よる苦味官能試験によって苦味の評価を行った。各パネ
ラーは検体10mlを30秒間口に含んだ後の苦味程度
を評価した。苦味程度は、非常に苦い(5点)、苦い
(4点)、少し苦い(3点)、ほとんど苦味感じない
(2点)及び全く苦くない(1点)の5段階の基準点数
で示し、各基準に対応するパネラーの人数を乗じて総合
評価点とした。総合評価点数の大きいものほど苦味が強
く、小さいほど苦味が弱い。
II. Bitterness Evaluation Test A bitterness evaluation test was carried out using the suspensions prepared in Examples and Reference Examples. The results were as shown in Table 3. (Test method) The bitterness was evaluated by a bitterness sensory test by 10 panelists (8 boys and 2 girls). Each panelist evaluated the degree of bitterness after containing 10 ml of the sample in the mouth for 30 seconds. The bitterness is indicated by a five-point standard score of very bitter (5 points), bitter (4 points), a little bitter (3 points), hardly bitter (2 points) and no bitterness (1 point). The overall evaluation score was obtained by multiplying the number of panelists corresponding to each standard. The higher the overall evaluation score, the stronger the bitterness, and the smaller the score, the weaker the bitterness.

【0019】下記表3の結果からは、実施例1〜4の処
方で得られる本発明の懸濁液剤がウルソデスオキシコー
ル酸の苦味をほとんど感じさせないものであることが判
る。一方、参考例1の処方の懸濁液剤は、苦味が非常に
強いものであった。参考例2の懸濁液剤は、苦味がマス
キングされていないものである。参考例3の懸濁液剤
は、苦味の抑制は少し改善されているが、本発明の懸濁
液剤と較べると抑制が不充分であることが判る。結果と
して、実施例1〜4の製法で調製された懸濁液剤は、キ
サンタンガムとヒドロキシプロピルスターチを配合する
ことによる相乗効果により、苦味がマスキングされたも
のと考えられる。ちなみに、単独配合した参考例2と3
の場合には苦味のマスキング効果が見られない。
From the results shown in Table 3 below, it can be seen that the suspensions of the present invention obtained by the formulations of Examples 1 to 4 hardly give the bitterness of ursodesoxycholic acid. On the other hand, the suspension of the formulation of Reference Example 1 had a very strong bitterness. The suspension of Reference Example 2 is one in which the bitterness is not masked. The suspension of Reference Example 3 shows a slight improvement in the suppression of bitterness, but it is found that the suppression is insufficient as compared with the suspension of the present invention. As a result, the suspensions prepared by the production methods of Examples 1 to 4 are considered to have bitterness masked due to the synergistic effect of mixing xanthan gum and hydroxypropyl starch. By the way, Reference Examples 2 and 3 which were independently blended
In the case of, the bitterness masking effect is not seen.

【0020】[0020]

【表3】 [Table 3]

【0021】以上の結果から、上記実施例1〜4の処方
で得られる本発明の懸濁液剤は、長期間保存しても沈降
分離が起こり難く、且つ再分散性が極めて良好であり、
しかもウルソデスオキシコール酸の苦味もほとんど感じ
させないものであることがわかる。一方、参考例1の処
方の懸濁液剤は沈降分離が激しく、再分散させることが
極めて困難な製剤であり、苦味も非常に強いものであっ
た。参考例2の懸濁液剤については沈降分離は起こり難
く分散性もほぼ良好であるが、苦味がマスキングされて
いないものである。又、参考例3の懸濁液剤は沈降分離
が参考例1のものほどではないが未だ大きく、しかも加
温条件下で次第に沈降率が増加する傾向を示し、又再分
散させるにも困難性を伴うものである。この場合に苦味
の抑制は少し改善されているが、本発明の懸濁液剤と較
べると抑制が不充分であることが判る。結果として、実
施例1〜4の製法で調製された懸濁液剤は、キサンタン
ガムとヒドロキシプロピルスターチを配合することによ
る相乗効果により、苦味がマスキングされたものと考え
られる。ちなみに、単独配合した参考例2と3の場合に
は苦味のマスキング効果が見られない。又本発明の懸濁
液剤は均一性が良く、且つ苦みがないばかりでなく、舌
触りがよく、服用し易いものである。
From the above results, the suspensions of the present invention obtained by the formulations of Examples 1 to 4 described above are unlikely to cause sedimentation separation even when stored for a long period of time, and have extremely good redispersibility,
Moreover, it can be seen that the bitterness of ursodesoxycholic acid is hardly felt. On the other hand, the suspension of the formulation of Reference Example 1 was a formulation that was extremely difficult to re-disperse because it had a strong sedimentation separation, and had a very strong bitterness. The suspension agent of Reference Example 2 hardly causes sedimentation and has good dispersibility, but the bitterness is not masked. Also, the suspension agent of Reference Example 3 has a larger sedimentation separation than that of Reference Example 1, but it is still large, and the sedimentation rate tends to gradually increase under heating conditions, and it is difficult to redisperse it. It is accompanied. In this case, the suppression of bitterness was slightly improved, but it was found that the suppression was insufficient as compared with the suspension of the present invention. As a result, the suspensions prepared by the production methods of Examples 1 to 4 are considered to have bitterness masked due to the synergistic effect of mixing xanthan gum and hydroxypropyl starch. By the way, in the case of Reference Examples 2 and 3 which were blended alone, no bitterness masking effect was observed. Further, the suspension of the present invention is not only good in uniformity and has no bitterness, but also has a good texture and is easy to take.

【0022】[0022]

【発明の効果】本発明により、舌触りなどが良くて飲み
易く、消化剤の強い苦味がマスキングされていて、且つ
長期間保存しても無機制酸剤などの成分が安定な懸濁状
態を維持でき、しかも、一旦沈降分離した場合であって
も容易に再分散させることができる懸濁液剤を提供する
ことができた。本発明の懸濁液剤は長期間保存した際に
沈降分離した場合であっても再分散が容易に、しかも短
時間で行えるなどの特徴を有し、消化促進、消化不良、
食欲不振、食べ過ぎ、胃もたれ、胸つかえ、消化不良な
どによる胃部・腹部膨満感、胃痛、胃酸過多などの症状
の改善に用いられる懸濁液剤として極めて有用である。
EFFECTS OF THE INVENTION According to the present invention, the texture and the like are easy to drink, the strong bitterness of the digestive agent is masked, and the components such as the inorganic antacid maintain a stable suspended state even after long-term storage. Further, it was possible to provide a suspension agent which can be easily redispersed even when it is once separated by sedimentation. The suspension of the present invention has a feature that it can be easily redispersed even when it is precipitated and separated when stored for a long period of time, and that it can be carried out in a short time.
It is extremely useful as a suspension agent for improving symptoms such as anorexia, overeating, stomach upset, chest tightness, bloating due to indigestion, gastric pain, and gastric hyperacidity.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 35/413 A61K 35/413 47/36 47/36 H L //(A61K 33/06 31:575) (A61K 33/06 35:413) (A61K 33/06 35:37) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display area A61K 35/413 A61K 35/413 47/36 47/36 H L // (A61K 33/06 31: 575) (A61K 33/06 35: 413) (A61K 33/06 35:37)

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】0.01〜0.05W/V%の消化剤、2
〜20W/V%の無機制酸剤、0.01〜5W/V%の
キサンタンガム、0.1〜20W/V%の化工デンプン
からなることを特徴とする懸濁液剤。
1. A digestive agent of 0.01 to 0.05 W / V%, 2.
-20 W / V% of inorganic antacid, 0.01-5 W / V% of xanthan gum, 0.1-20 W / V% of modified starch.
【請求項2】消化剤が、ウルソデスオキシコール酸、オ
キシコーラン酸、デヒドロコール酸、コール酸、胆汁
末、胆汁エキス、動物胆の群から選ばれる1種又は2種
以上のものである特許請求の範囲第1項記載の懸濁液
剤。
2. A patent wherein the digestive agent is one or more selected from the group consisting of ursodesoxycholic acid, oxycholanic acid, dehydrocholic acid, cholic acid, bile powder, bile extract and animal gall. The suspension agent according to claim 1.
【請求項3】無機制酸剤が、メタケイ酸アルミン酸マグ
ネシウム、ケイ酸アルミン酸マグネシウム、合成ヒドロ
タルサイト、水酸化アルミニウムゲル、水酸化マグネシ
ウムからなる非水溶性無機制酸剤の群から選ばれる1種
又は2種以上のものである特許請求の範囲第1項記載の
懸濁液剤。
3. The inorganic antacid selected from the group of water-insoluble inorganic antacids consisting of magnesium aluminometasilicate, magnesium aluminate silicate, synthetic hydrotalcite, aluminum hydroxide gel, magnesium hydroxide. The suspension agent according to claim 1, which is one kind or two or more kinds.
【請求項4】化工デンプンが、ヒドロキシプロピルスタ
ーチ、部分アルファー化デンプン類、デキストリン類よ
り選ばれる1種又は2種以上のものである特許請求の範
囲第1項記載の懸濁液剤。
4. The suspension according to claim 1, wherein the modified starch is one kind or two or more kinds selected from hydroxypropyl starch, partially pregelatinized starches and dextrins.
JP8110385A 1996-04-05 1996-04-05 Suspension formulation Pending JPH09278661A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8110385A JPH09278661A (en) 1996-04-05 1996-04-05 Suspension formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8110385A JPH09278661A (en) 1996-04-05 1996-04-05 Suspension formulation

Publications (1)

Publication Number Publication Date
JPH09278661A true JPH09278661A (en) 1997-10-28

Family

ID=14534474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8110385A Pending JPH09278661A (en) 1996-04-05 1996-04-05 Suspension formulation

Country Status (1)

Country Link
JP (1) JPH09278661A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051384A1 (en) * 2000-12-25 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing suspension and stabilized suspension
JP2007269789A (en) * 2006-03-07 2007-10-18 Lion Corp In-oral cavity disintegrable tablet
KR20110028177A (en) * 2009-09-11 2011-03-17 주식회사 대웅제약 Ursodesoxycholic acid-synthetic hydrotalcite-eudragit nanohybrid, pharmaceutical composition containing the same and method for preparing the same
JP2011527733A (en) * 2008-07-09 2011-11-04 ナルコ カンパニー Compositions and methods for deinking cellulosic substrates using magnesium hydroxide
JP2013542917A (en) * 2010-08-13 2013-11-28 コンパニ・ジェルベ・ダノン Products for upper stomach area
JP2018527371A (en) * 2015-09-16 2018-09-20 ラボラトワ シー.ティー.アール.エス. Pediatric preparations containing bile acids
KR101999073B1 (en) * 2018-12-29 2019-07-10 김민재 Composition for supporting administration to animal and methods for preparing the same

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051384A1 (en) * 2000-12-25 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing suspension and stabilized suspension
JPWO2002051384A1 (en) * 2000-12-25 2004-04-22 中外製薬株式会社 Suspension stabilization method and stabilized suspension
JP2007269789A (en) * 2006-03-07 2007-10-18 Lion Corp In-oral cavity disintegrable tablet
JP2011527733A (en) * 2008-07-09 2011-11-04 ナルコ カンパニー Compositions and methods for deinking cellulosic substrates using magnesium hydroxide
KR20110028177A (en) * 2009-09-11 2011-03-17 주식회사 대웅제약 Ursodesoxycholic acid-synthetic hydrotalcite-eudragit nanohybrid, pharmaceutical composition containing the same and method for preparing the same
US20120156263A1 (en) * 2009-09-11 2012-06-21 Daewoong Pharmaceutical Co., Ltd. Ursodeoxycholic Acid-Synthetic Hydrotalcite-Eudragit Hybrid, Pharmaceutical Composition Containing the Same and Method for Preparing the Same
JP2013542917A (en) * 2010-08-13 2013-11-28 コンパニ・ジェルベ・ダノン Products for upper stomach area
JP2018527371A (en) * 2015-09-16 2018-09-20 ラボラトワ シー.ティー.アール.エス. Pediatric preparations containing bile acids
KR101999073B1 (en) * 2018-12-29 2019-07-10 김민재 Composition for supporting administration to animal and methods for preparing the same

Similar Documents

Publication Publication Date Title
US4965252A (en) Cholesterol-lowering combination compositions of guar gum and niacin
JPH0952835A (en) Peroral medicine constitution
CA2958925C (en) Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions
WO2010092468A1 (en) Composition comprising alginates and d-limonene to treat gerd and dyspepsia
JP2004099558A (en) Jelly formulation for pharmaceutical use
JPH09278661A (en) Suspension formulation
JPS62153220A (en) Water-based bile acid agent for internal use
CN106727272A (en) A kind of mouthwash formulation and method of gargling
WO2003063856A1 (en) Jelly preparation containing branched amino acids
JPS62259552A (en) Guar powder
JP2004059503A (en) Chinese medicine-based jellylike pharmaceutical composition
JP3751987B2 (en) Hangover prevention or improvement agent
JPH08503926A (en) Sugar-free dry mix cellulose ether composition as bulk laxative
TWI235663B (en) Oral liquid preparations
JPH0698729A (en) Ginseng extract-containing beverage and its production
JPH0696536B2 (en) Internal suspension containing antacid
KR101458670B1 (en) Pharmaceutical composition comprising branched chain amino acids as active ingredients and the preparation method thereof
AU663693B2 (en) Psyllium and cholestyramine compositions with improved palatability
JPS63258820A (en) Stegnotic-containing suspension for internal use
JP4204864B2 (en) Suspension stabilization method and stabilized suspension
JP2003104881A (en) Suspension for internal application
JPS63132840A (en) Suspended antacid agent
IE51847B1 (en) Pharmaceutical formulation
JPH05308903A (en) Starch jelly
JPH0952845A (en) Enzyme-containing internal liquid medicine having high shelf stability